Atlas Trials

Clinical Study of Apatinib as the Second-line Therapy in Malignant Melanoma

Clinical trial NCT03383237 · UNKNOWN

Trial details

NCT number
NCT03383237
Sponsor
Henan Cancer Hospital
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Malignant Melanoma
Start date
2017-11-29
Primary completion
2018-11-01
Enrollment
20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.